SPDR S&P Biotech ETF
0
Funds holding %
of 7,372 funds
–
Analysts bullish %
Fund manager confidence
Based on 2024 Q4 regulatory filings by fund managers ($100M+ AUM)
10.73% more ownership
Funds ownership: 145.3% [Q3] → 156.02% (+10.73%) [Q4]
5% less funds holding
Funds holding: 759 [Q3] → 719 (-40) [Q4]
14% less capital invested
Capital invested by funds: $11.4B [Q3] → $9.8B (-$1.57B) [Q4]
15% less first-time investments, than exits
New positions opened: 99 | Existing positions closed: 117
29% less funds holding in top 10
Funds holding in top 10: 21 [Q3] → 15 (-6) [Q4]
31% less repeat investments, than reductions
Existing positions increased: 190 | Existing positions reduced: 276
38% less call options, than puts
Call options by funds: $2.07B | Put options by funds: $3.32B
Research analyst outlook
We haven’t received any recent analyst ratings for XBI.
Financial journalist opinion
Based on 5 articles about XBI published over the past 30 days
Neutral
CNBC Television
1 week ago
Single stock picking is the only way to make money in biotech, says Mizuho's Jared Holz
Jared Holz, Mizuho health care equity strategist, joins 'Power Lunch' to discuss investing in biotech and the oversaturation in the sector.
Neutral
CNBC Television
1 week ago
Trade Tracker: Joe Terranova sells the XBI, buys Amgen
Joe Terranova, Senior Managing Director for Virtus Investment Partners, joins CNBC's "Halftime Report" to detail his latest portfolio moves.
Neutral
Zacks Investment Research
1 week ago
Is SPDR S&P Biotech ETF (XBI) a Strong ETF Right Now?
The SPDR S&P Biotech ETF (XBI) made its debut on 01/31/2006, and is a smart beta exchange traded fund that provides broad exposure to the Health Care ETFs category of the market.
Positive
Seeking Alpha
1 week ago
Invest In A New Biotech Bull Market With XBI And IBB
Biotech stocks are oversold. This near-term bottom might be the start of a long-term bull run. IBB and XBI offer different advantages. IBB can benefit from the flight to safety trade. XBI provides more leverage to the biotech turnaround trade. Falling interest rates, weak GDP growth, low inflation, and Fed rate cuts mean the macro environment is ripe for biotech.
Neutral
Seeking Alpha
2 weeks ago
Seeking Stocks With Vitality In The Volatile Healthcare Sector
Investors cooled to the healthcare sector in 2024, which dramatically trailed global and US equity markets for the year. any investors are now asking: how will the policy changes under a new US administration affect healthcare companies?
Neutral
GlobeNewsWire
1 month ago
Shareholder Group Led by Founder Mina Sooch Nominates Majority Slate of Director Candidates to the Board of Opus Genetics, Inc.
Current Board's Strategic, Management, and Capital Allocation Failures Have Driven an 80% Stock Decline Over Last 22 Months
Positive
ETF Trends
1 month ago
Can Health Care ETFs Aid Your Portfolio?
The Health Care Select Sector SPDR ETF (XLV) was up approximately 6% year-to-date as of January 29. While it is still early days, this performance is already twice as robust as the sector ETF's performance for all of 2024.
Neutral
Zacks Investment Research
1 month ago
Should You Invest in the SPDR S&P Biotech ETF (XBI)?
Designed to provide broad exposure to the Healthcare - Biotech segment of the equity market, the SPDR S&P Biotech ETF (XBI) is a passively managed exchange traded fund launched on 01/31/2006.
Positive
Seeking Alpha
1 month ago
XBI: Diverse Holding Amid Strong Catalysts, Buy
SPDR® S&P Biotech ETF is a strong investment due to rising demand for biotech solutions addressing chronic diseases and its diverse, equal-weighted portfolio. XBI's equal-weighting strategy reduces concentration risk and balances risk-reward by investing in large, mid, and small-cap biotech companies. Strong industry trends and government support, including increasing NIH funding, bolster XBI's long-term growth potential despite short-term volatility from RFK's appointment.
Positive
Seeking Alpha
1 month ago
3 Biotech Stocks With Notable Insider Buying
Small biotech stocks have struggled recently, with the SPDR® S&P Biotech ETF down over 15% in the past ten weeks. The pullback has presented significantly lower entry points on myriad small and mid-cap biotech and biopharma stocks. Today, we look at three of these names that have seen notable recent purchases from insiders and/or beneficial owners.
Charts implemented using Lightweight Charts™